Physician profile
Mark Rex Rosenthall
NPI 1417515255
$1,890.69
in general payments reported to CMS, 2019-2025
9 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Orthodontics and Dentofacial Orthopedics provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $145 · 2021: $213 · 2022: $397 · 2023: $381 · 2024: $356 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984 · Charitable Contribution: $30.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.41 |
| Charitable Contribution | $30.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ormco Corporation | $651.37 | 2019-2023 | Spark |
| Envista Holdings Corporation | $607.05 | 2024-2025 | Spark, Damon 3 |
| Align Technology, INC. | $272.78 | 2019-2025 | Touch Up, Invisalign, Itero Element 5d Plus Lite |
| Nobel Biocare USA | $137.91 | 2021-2023 | Nobelactive |
| Gc America INC. | $65.88 | 2022 | |
| American Orthodontics Corporation | $51.98 | 2022 | |
| Scican INC | $50.95 | 2019 | |
| 3m Company | $38.07 | 2019 | |
| Dentsply Sirona INC | $14.70 | 2025 | Suresmile |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rosenthall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.